Business Daily Media

Men's Weekly

.

Yingli Pharma Announces NMPA Approval of New Anti-cancer Drug Linperlisib

The first highly selective PI3Kδ inhibitor in China

SHANGHAI, CHINA - Media OutReach - 9 November 2022 - Shanghai Yingli Pharmaceutical Co., Ltd. (the "Company" or "Yingli Pharma") is pleased to announce that linperlisib, trade name因他瑞®, a novel phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, has been approved by the National Medical Products Administration (NMPA) of China on November 9 for the treatment of relapsed/refractory follicular lymphoma (R/R FL) in patients who have received 2 or more prior systemic therapies. The NDA approval validates Yingli Pharma’s strong innovation capabilities and fulfills the company’s objectives to bring new treatment options to patients and their families.

Picture-12.png
[Photo: NMPA Approval of linperlisib]

Yingli Pharma has entered into strategic partnership with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a leading pharmaceutical company with well-established oncology sales and marketing network, to commercialize因他瑞® in China.

A safe and effective treatment choice for FL patients

Linperlisib is a next generation phosphoinositide 3-kinase delta (PI3Kδ) inhibitor independently developed by the Company. PI3Kδ plays a key role in the tumor immune cell proliferation and survival, making it a potent target for non-Hodgkins lymphomas. Treatment options for R/R FL patients, a major form of non-Hodgkins lymphoma, are extremely limited in China. In 2020, linperlisib was awarded NMPA Breakthrough Therapy status for the treatment of R/R FL in China. In addition, it received U.S. Food and Drug Administration (FDA) Orphan Drug Designations for FL, Chronic lymphocytic leukemia/ small lymphocytic lymphoma and T cell lymphoma.

In the pivotal R/R FL Phase II clinical trial in China, linperlisib-treated patients had an 79.8% overall response rate, a 96.6% disease control rate, a median Time to Response of 1.9 months, a median Progression Free Survival of 13.4 months, Duration of Response of 12.3 months and a 91.4% overall survival rate at 12 months1. Linperlisib was well-tolerated with a differentiated and manageable safety profile, with low immune-mediated toxicities. In the linperlisib-treated patient safety dataset of the pivotal study, the most common (>15%) non-hematologic treatment related adverse events (TRAE) (Any Grade/ Grade3) were hypertriglyceridemia (25%/3%), ALT elevation (19%/2%), AST elevation (15%/2%), diarrhea (15%/2%), and pneumonia (15%/15%). The most common (>5%) hematologic TRAEs (Grade3) were neutropenia (15%), leukocytopenia (5%), and lymphocytopenia (5%).

“We are pleased to provide a new treatment option for patients with R/R FL with the approval of linperlisib. As linperlisib is the first innovative drug independently developed by Yingli Pharma, the NDA approval is a significant milestone”, said Dr. Xu Zusheng, General Manager and President of R&D of Yingli Pharma, “We would like to thank the patients, clinicians, and scientists for their generosity and great effort in the clinical development of linperlisib. It is a convenient once daily oral drug which demonstrated favorable safety, promising efficacy and great patient compliance. Yingli Pharma looks forward to in-depth collaboration with Hengrui Pharma to bring forth a full commercialization of 因他瑞® and extend the clinical development into additional indications.”

Dr. Lianshan Zhang, Deputy General Manager and President of Global R&D of Hengrui Pharma, said, " We are delighted with the NDA approval of linperlisib (因他瑞) for R/R FL. This approval is an important step for Hengrui Pharm to build a strong hematology franchise with an enriched pipeline. As Hengrui Pharma focuses on patient-centered R&D and innovation, we will continue to evaluate new indications for linperlisib, and combinations with the company's existing products to potentially benefit more patients.”

1. Lugui Qiu et al. 2022EHA.Abstract 1119

Hashtag: #YingliPharma

About Yingli Pharma

Shanghai Yingli Pharmaceutical Co., Ltd. is a technologically innovative biopharmaceutical company founded in 2011 and located in the National Biomedical Industry Base of Shanghai Zhangjiang InnoPark. With the Chinese government promotion of healthcare reforms, the Chinese pharmaceutical industry has gradually transformed to include the biopharmaceutical sector of innovation. The NDA approval of linperlisib is a significant milestone for this national effort and demonstrates the Company’s strong innovation capability for drug development. Yingli Pharma has established a rich and independently-developed pipeline of novel oral agents for oncology and metabolic diseases. The Company has more than ten drugs under development, including more than 100 independent intellectual property rights, with three of the investigational agents in clinical stage in China and abroad.

For more information, please see:


News from Asia

Prudential and Prudence Foundation Provide Free Mental Health Support to Vulnerable Communities

In partnership with Intellect, the programme will be launched in Malaysia and Vietnam to make mental healthcare more accessible for vulnerable or at-risk groups HONG KONG SAR - Media OutReach News...

Trend Micro Named a Leader in IDC MarketScape for CNAPP

HONG KONG SAR - Media OutReach Newswire - 2 July 2025 - Trend Micro Incorporated (TYO: 4704; TSE: 4704), a global cybersecurity leader, today announced it has been named as a Leader in the IDC Ma...

Drug & Medical Device & Aesthetics, 肌顏態 was displayed at the CSD2025, The GeneQueens and 金因敷 launch was grandly held in Changsha

HONG KONG SAR - EQS Newswire - 2 July 2025 - On June 27, 2025, Uni-Bio Science Group Limited (the "Group")grandly held a new medical aesthetics product launch event in Changsha, releasing the high-...

Amazon Singapore Unveils a Week of Prime Day Deals and a Special Public Maze Event for Prime Day 2025

Prime members can access exclusive deals from brands such as Neutrogena, FOREO, Resto, Cricut, Pigeon, PicassoTiles and Coca-Cola from 8 – 14 July. Free Public event: Amazon Prime Day Maze at Sun...

Themed Forum of "Mountain Biodiversity and Our Life" to Kick off "Guizhou Example" Empowering Global Mountain Eco-treatment

GUIYANG, CHINA - Media OutReach Newswire - 2 July 2025 - Recently, Eco Forum Global Guyang 2025 announced at a press briefing that the themed forum "Mountain Biodiversity and Our Life" will be hel...

Asia's First Porsche Design Tower Offers Revolutionary Luxury Living Experience to Bangkok's Vibrant Japanese Community

STUTTGART, GERMANY / TOKYO, JAPAN - Media OutReach Newswire - 24 June 2025 - Porsche Design Tower Bangkok emerges as a defining statement of excellence in luxury automotive-inspired living. As Asi...

Chubb Life Hong Kong Launches Chubb 1792 Club, a Prestigious Global Wealth Centre Designed to Elevate Customer Experience

HONG KONG SAR - Media OutReach Newswire - 16 June 2025 - Chubb Life Hong Kong (Chubb Life HK) today unveiled its first wealth centre, Chubb 1792 Club, marking a pivotal moment in its insurance and...

Cushman & Wakefield Greater China Wins Three Best Five-Star Awards at 2025 Asia Pacific Property Awards

HONG KONG SAR - Media OutReach Newswire - 19 June 2025 - Cushman & Wakefield, a leading global real estate services firm, has again been recognized at the Asia Pacific Property Awards, scoring...

Cushman & Wakefield and Corenet Global Release New Survey Results On "What Occupiers Want"

Cost remains king, but talent, flexibility, and service are reshaping real estate strategy globally HONG KONG SAR - Media OutReach Newswire - 2 July 2025 - Cushman & Wakefield (NYSE: CWK), in ...

Hong Kong banks showed moderate balance sheet growth amid global uncertainty in 2024, KPMG report finds

Disciplined cost management, risk vigilance, and digital innovation underpin sector resilience HONG KONG SAR - Media OutReach Newswire - 2 July 2025 – Hong Kong's banking sector demonstrated stead...

The Next Generation of Maritime Sustainable Solutions

As organizations globally seek innovative ways to improve sustainability and their impact on Earth, the American Waterways Operators (AWO), a lead...

Demand for Home Batteries surges as Federal Rebate Kicks In

A leading provider of energy solutions VoltX Energy has seen a 400% increase in demand for home batteries in the past three weeks as people put d...

Why Sport Remains the Safest Bet in an Uncertain World

When Rome was in crisis, its leaders did not retreat to the Senate. They went to the circus. To the chariot races. To the gladiators. Sport was no...

THE FINE LINE WITHIN HILARIOUS SIGNAGE DESIGN FAILS

It seems like design failures still occur in today’s modern branding era, despite rigorous rounds of approvals behind the scenes. One signage show...

Deputy Announces Exclusive Global Partnership with Predelo to Bring AI to Shift-Based Businesses

Deputy, the global people platform for shift-based businesses, has announced an exclusive partnership with Predelo, an AI Decision Agent-as-a-Serv...

Leftover Budget? The Last-Minute EOFY Tip to Drive Business Success in FY25/26

The countdown is on. With just days left until EOFY, now’s the time to make your remaining 2024–2025 budget work harder and smarter. After workin...

Sell by LayBy